Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14377614 | 0.83 | SMYD3 (0.44) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL13058648 | 0.83 | SMYD3 (0.44) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL15859848 | 0.83 | SMYD3 (0.44) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL1464146 | 0.82 | SMYD3 (0.41) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL1445829 | 0.82 | SMYD3 (0.41) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL1445966 | 0.82 | SMYD3 (0.41) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1445815 | 0.81 | SMYD3 (0.40) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1464088 | 0.81 | SMYD3 (0.40) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL3274629 | 0.78 | GPR88 (0.37) | SMYD3KMT2ASMN1; SMN2GPR88L3MBTL1 | |
| SCHEMBL329101 | 0.78 | SMYD3 (0.43) | SMYD3KMT2ASMN1; SMN2GPR88SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247532-B2 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225297-A1 | Deuterated hepatitis C protease inhibitors | PEPD, CTRL, CTSC | SMYD3 3675/4885KMT2A 1109/4885SMN1; SMN2 4416/4885 |
| US-20110071074-A1 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS | PEPD, CTRL, CTSC | SMYD3 3675/4885KMT2A 1109/4885SMN1; SMN2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.